Bronchopulmonary dysplasia: Clinical perspective

Research output: Contribution to journalArticlepeer-review

50 Scopus citations


Since Northway's original description of BPD almost 45 years ago, the clinical presentation of BPD has evolved into a disease process, which mostly involves extremely premature infants. This new form of BPD is the result of multiple antenatal and postnatal factors that can cause injury to the developing lung leading to altered alveolar and vascular development. Over the years, there has been considerable increase in knowledge of factors that contribute to the development of BPD. This has led to different strategies for prevention as well as management of BPD. Some of these strategies have been successful and have withstood the test of clinical trials, such as vitamin A supplementation, post-natal steroids, caffeine, and volume targeted ventilation. The evidence for other interventions has been weak or negative. With better understanding of the complex and multifactorial pathogenesis of BPD, it is quite clear that any single therapy is very unlikely to eliminate this problem unless it reduces prematurity. Further development in prevention and treatment of BPD will likely need a multi-pronged strategy with novel therapeutic agents acting at various stages of the disease process.

Original languageEnglish (US)
Pages (from-to)134-144
Number of pages11
JournalBirth Defects Research Part A - Clinical and Molecular Teratology
Issue number3
StatePublished - Mar 2014


  • BPD
  • Clinical presentation
  • Management
  • Premature
  • Prevention

ASJC Scopus subject areas

  • Developmental Biology
  • Pediatrics, Perinatology, and Child Health
  • Embryology


Dive into the research topics of 'Bronchopulmonary dysplasia: Clinical perspective'. Together they form a unique fingerprint.

Cite this